Autopsy report · NCT06549296

Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases

“R\&D strategy adjustment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Suspended: paused, and may or may not restart.
• 12 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Phase

Early Phase 1

Sponsor

Nanjing Bioheng Biotech Co., Ltd.

Sponsor type

Industry

Conditions

Systemic Lupus Erythematosus; Systemic Sclerosis; ANCA Associated Vasculitis; Idiopathic Inflammatory Myopathies; Sjogren's Syndrome; Autoimmune Diseases

Interventions

RD06-04 CART Cell Injection

Participants

12 (planned, not actual)

Sites

1

Countries

China

Trials that died the same way

• A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC
  “changes in the R\&D strategy” (86% match in meaning)
• A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors
  “Sponsor R \& D Strategy Adjustment” (76% match in meaning)
• Choroidal Changes Post Short Term Exposure To Virtual Reality Devices
  “Strategy change” (69% match in meaning)
• Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma
  “Change in strategy” (69% match in meaning)
• A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
  “Sponsor's R\&D strategy adjusted.” (67% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.